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COMMENTARY 
ER Stress as a Trigger for (3-Cell Dysfunction and 
Autoimmunity in Type 1 Diabetes 
Bryan O'SuJJivan -Murphy and Fwnihiko Urano 
ype 1 diabetes is an autoimmune disease char-
actelized by the destruction of pancreatic 13-cells 
and an absolute deficiency of insulin. Patients 
with type 1 diabetes are insulin dependent for 
life and require multiple daily insulin ir\jections or the use 
of an insulin pump. It has been considered that 13-cell 
dysfunction and death in type 1 diabetes results from a 
combination of inflammation, autoimmunity, 13-cell stress, 
and insulin resistance (1-5). Clinical and experimental 
evidence has indicated that defects in 13-"Cell function pre-
cede the massive death of 13-cells by severe infiltration of 
T cells into the islets and the clinical onset of type 1 di-
abetes (6-9). However, the mechanisms involved in 13-cell 
dysfunction before the onset of clinical type 1 diabetes are 
unclear. In this issue of Diabetes, Tersey et al. (10) add 
a new dimension to the progression of type 1 diabetes by 
demonstrating that endoplasmic reticulum (ER) stress in 
13-cells precedes the clinical onset of type 1 diabetes. 
ER STRESS AS A TRIGGER FOR fl-CELL DYSFUNCTION 
IN TYPE 1 DIABETES 
The ER peliorms a nun1ber of important cellular tasks, 
including protein folding, calcium regulation, redox regu-
lation, and life or death decisions (11,12). Within the 13-cell, 
insulin production and secretion depend on the processing 
capacity of the ER network. Thus, the ER of the 13-cell 
must maintain homeostatic balance in order to efficiently 
produce insulin and maintain viability. Perturbations to 
the ER by genetic or environmental factors can disrupt 
ER homeostasis and lead to tl1e development of ER stress. 
Unresolved ER stress has deletelious effects on pancre-
atic 13-cell function and survival, and it can influence the 
progression of diabetes (11,13). Using NOD mice, a well-
established model of type 1 diabetes, Tersey et al. (10) 
demonstrated activation of ER stress pathways in 13-cells 
plior to the onset of type 1 diabetes. Isolated islets from 
prediabetic NOD mice displayed age-dependent increases 
in expression of ER stress markers, morphologic alteration 
in ER structure by electron microscopy, and activation of 
the nuclear factor (NF)-KB pathway, which is known to 
be linked to ER stress. Tersey et al. also showed that 
MIN6 13-cells treated with a mixtw·e of proinflammatory 
cytokines, a condition that mimics the immunological 
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microenvironment of type 1 diabetes, displayed evidence 
of polyribosomal runoff, a finding consistent with ER 
stress- mediated blockage of translational initiation. Re-
cent clinical and genetic evidence indicates that acquired 
or inhe1ited ER dysfunction can lead to 13-"Cell deatl1 in 
Wolfram syndrome, a rare genetic form of diabetes, as well 
as 13-cell death in both type 1 and type 2 diabetes. While the 
role of ER stress in the pathogenesis of type 2 diabetes is 
well established (14,15), the involvement of this pathway 
in type 1 diabetes remained elusive. The results of Tersey 
et al. clearly indicate that ER stress is an important path-
ogenic component of 13-cell dysfunction before the onset 
of type 1 diabetes. 
TARGETING ER STRESS FOR PREVENTING (l-CELL 
DYSFUNCTION AND AUTOIMMUNlTY IN TYPE 1 DIABETES 
As always, new findings raise new questions. The most 
intriguing question might be, what are the consequences of 
ER stress-mediated ~-cell dysfunction in type 1 diabetes? 
The authors (10) provide compelling evidence that the 
NF-KB pathway is activated in ER-stressed 13-cells prior to 
the onset of type 1 diabetes. NF-KB has been shown to play 
an important role in 13-cell deatl1 during progression of 
type 1 diabetes. Thus, ER-stressed 13-cells in prediabetic 
NOD mice could eventually die through NF-KB signaling 
and lead to frank diabetes. Another interesting possibility 
is fuat ER stress in 13-cells may trigger autoimmunity and 
the severe infiltration ofT cells into the islets (Fig. 1). Type 1 
diabetes is an autoimmune disease that evolves over 
years in genetically susceptible individuals who are ex-
posed to unknown environmental tliggers. In1p01tantly, all 
major 13-cell autoantigens, including insulin, GAD65, IA-2, 
ZnT-8, and chromogranin A, traffic through the ER (16). 
ER dysfunction may cause aberrant changes in the folding 
and posttranslational modifications of these proteins, 
leading to the production of neo-self antigens. Neo-self 
antigens produced from ER-stressed 13-cells may u·igger 
autoinunwuty in individuals with a susceptible genetic 
background. In either case, now it is possible to determine 
subjects with high risk for type 1 diabetes with greater 
precision using biomarkers for ER-stressecl 13-cells. The 
fact that ER function is altered in type 1 diabetes suggests 
the possibility of using secreted molecules from ER-
stressed ~-cells as early biomarkers of type 1 diabetes 
progression. The data by Tersey et al. (10) also suggest 
fuat chemical or biological compounds that maintain ER 
homeostasis could be used for therapeutic purposes. To 
date, there are no effective therapies targeting U1e ER for 
preventing type 1 diabetes. A novel tl1erapeutic strategy 
that aims to target tile common molecular processes that 
are altered in ER-stressed 13-cells may therefore offer 
promise. Because preventing type 1 diabetes before 13-cell 
function decreases below clitical levels may prove to be 
less challenging than curing established type 1 diabe-
tes (17), further studies on this topic are particularly 
diabetes.diabete!ijoumals.org 
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F I G. 1. ER stress as a trigger for (3-ceU dysfunction and autoinunu11ity in 
type 1 diabetes. ER-stressed (3-ceUs i n early type 1 diabetes could even-
tually die through NF-KB signaliJ1g and lead to frank diabetes. Another 
possibility is tJ1at ER-stressed (3-ceUs may produce neo-autoa.ntigens and 
trigger autoinUtm.nity, leading to a sever e inftltration ofT ceUs into islets. 
(A high-quality color representation of tJlis figure is available in tbe 
online issue.) 
important for the development of novel prevention, diag-
nostic, and therapeutic strategies for type 1 diabetes. 
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